Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Vitas AS, Oslo Science Park, Oslo, Norway.
PLoS One. 2024 Sep 17;19(9):e0310170. doi: 10.1371/journal.pone.0310170. eCollection 2024.
Many aging men experience reduced energy and libido related to non-optimal testosterone levels. We conducted a randomized double-blind trial with TrigozimR fenugreek extract to assess impact on plasma and saliva testosterone, and some subjective effects. 95 men (40-80y) completed a 12-week intervention, taking 3 tablets daily with 0 mg (placebo; n = 22), 600 mg (n = 21), 1200 mg (n = 25) and1800 mg (n = 27) fenugreek extract and essential nutrients. Samples were collected at weeks 0, 2, 6, and 12. Participants answered a pre- and post-intervention questionnaire on lifestyle and libido. We measured total testosterone (HPLC-MS/MS) and sex hormone binding globulin (ELISA), calculated free testosterone index (FTI), and measured saliva testosterone. Plasma total testosterone and FTI increased after any dose of TrigozimR vs. baseline (13.0%, p = 1.0x10-4 and 16.3%, p = 6.2x10-6), but not vs. placebo (9.0%, p = 0.122 and 11.3% p = 0.059). 1800 mg TrigozimR resulted in 12.2% increased FTI (p = 0.025). Saliva testosterone concentration increased after any dose of TrigozimR vs. baseline (31.1%, p = 2.3x10-4) and vs. placebo (37.2%, p = 0.042). 1800 mg TrigozimR for 12 weeks resulted in 19.6% (p = 0.006) increased saliva testosterone. Compliance was confirmed by enhanced plasma concentration of 25-hydroxy vitamin D3. We observed no subjective effects or side-effects of TrigozimR. TrigozimR increased saliva and plasma testosterone concentration during intervention but only for saliva vs. placebo. Saliva may be preferred for measuring free testosterone due to no protein-bound testosterone.
许多老年男性由于睾丸激素水平不理想而出现精力和性欲下降的情况。我们进行了一项随机、双盲试验,使用 TrigozimR 葫芦巴提取物评估其对血浆和唾液睾丸激素以及一些主观效果的影响。95 名男性(40-80 岁)完成了为期 12 周的干预,每天服用 3 片,0 毫克(安慰剂;n = 22)、600 毫克(n = 21)、1200 毫克(n = 25)和 1800 毫克(n = 27)葫芦巴提取物和必需营养素。在 0、2、6 和 12 周时采集样本。参与者在干预前后回答了一份关于生活方式和性欲的问卷。我们使用 HPLC-MS/MS 测量总睾酮和性激素结合球蛋白(ELISA),计算游离睾酮指数(FTI),并测量唾液睾酮。与基线相比,任何剂量的 TrigozimR 都会增加血浆总睾酮和 FTI(13.0%,p = 1.0x10-4 和 16.3%,p = 6.2x10-6),但与安慰剂相比则不然(9.0%,p = 0.122 和 11.3%,p = 0.059)。1800 毫克 TrigozimR 使 FTI 增加 12.2%(p = 0.025)。与基线相比,任何剂量的 TrigozimR 都会增加唾液睾酮浓度(31.1%,p = 2.3x10-4)和安慰剂(37.2%,p = 0.042)。12 周内,1800 毫克 TrigozimR 使唾液睾酮增加 19.6%(p = 0.006)。通过 25-羟维生素 D3 血浆浓度的增加证实了依从性。我们没有观察到 TrigozimR 的任何主观影响或副作用。在干预期间,TrigozimR 增加了血浆和唾液中的睾丸激素浓度,但只有唾液与安慰剂相比有所增加。由于没有结合蛋白的睾丸激素,唾液可能更适合测量游离睾丸激素。